We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+25.17%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.8B
AUM Growth
+$1.58B
Cap. Flow
-$1.22B
Cap. Flow %
-8.22%
Top 10 Hldgs %
44.34%
Holding
132
New
32
Increased
38
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$317M
2
CRM icon
Salesforce
CRM
+$270M
3
TMO icon
Thermo Fisher Scientific
TMO
+$259M
4
MDCO
Medicines Co
MDCO
+$221M
5
PPLI
People Inc
PPLI
+$137M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.55B
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$754M
3
AABA
Altaba Inc
AABA
+$666M
4
BABA icon
Alibaba
BABA
+$196M
5
CTXS
Citrix Systems Inc
CTXS
+$183M

Sector Composition

Rank Sector Weight
1 Healthcare 46.6%
2 Communication Services 12.82%
3 Technology 9.97%
4 Industrials 5.05%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
76
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.6M 0.15%
175,000
-125,000
-42% -$12.1M
PRNB
77
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$21.9M 0.15%
+400,000
New +$14.9M
SVRA icon
78
Savara
SVRA
$1.15B
$21.6M 0.15%
4,825,086
+1,314,299
+37% +$1.58M
AMRN
79
CALL
Amarin Corp
AMRN
$298M
$21.4M 0.14%
+50,000
New +$19M
CRSP icon
80
CRISPR Therapeutics
CRSP
$5.75B
$21.3M 0.14%
350,000
-210,367
-38% -$11.5M
WMGI
81
DELISTED
Wright Medical Group Inc
WMGI
$21M 0.14%
+690,000
New +$18.1M
HRTX icon
82
Heron Therapeutics
HRTX
$60.4M
$20.6M 0.14%
+875,000
New +$19.4M
CY
83
DELISTED
Cypress Semiconductor
CY
$19.6M 0.13%
840,000
-1,624,966
-66% -$38M
GEN icon
84
Gen Digital
GEN
$17.3B
$18.4M 0.12%
720,000
-310,000
-30% -$7.57M
S
85
DELISTED
Sprint Corporation
S
$16.7M 0.11%
3,200,000
-3,034,186
-49% -$17.8M
EIGR
86
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$16.3M 0.11%
36,485
-1,015
-3% -$360K
PACB icon
87
Pacific Biosciences
PACB
$420M
$15.4M 0.1%
+3,000,000
New +$15.2M
RETA
88
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$15.3M 0.1%
75,000
-107,060
-59% -$19.5M
APLS
89
DELISTED
Apellis Pharmaceuticals
APLS
$15.3M 0.1%
+500,000
New +$13.8M
LVGO
90
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$15M 0.1%
+600,000
New +$14.3M
XGN icon
91
Exagen
XGN
$192M
$14.7M 0.1%
577,699
+214,363
+59% +$3.81M
QURE icon
92
uniQure
QURE
$3.36B
$14.3M 0.1%
200,000
+99,078
+98% +$5.44M
LOGM
93
DELISTED
LogMein, Inc.
LOGM
$11.2M 0.08%
+130,241
New +$9.66M
PTGX icon
94
Protagonist Therapeutics
PTGX
$9.99B
$10.6M 0.07%
1,500,000
– –
OPTN
95
DELISTED
OptiNose
OPTN
$8.3M 0.06%
+60,000
New +$7.78M
RCKT icon
96
Rocket Pharmaceuticals
RCKT
$385M
$8.06M 0.05%
+354,082
New +$5.91M
GCVRZ
97
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$7.91M 0.05%
9,195,584
+2,367,779
+35% +$1.82M
GOSS icon
98
Gossamer Bio
GOSS
$75.6M
$7.82M 0.05%
500,000
+399,288
+396% +$8.04M
DMTK
99
DELISTED
DermTech, Inc. Common Stock
DMTK
$7.63M 0.05%
615,385
– –
ABEO icon
100
Abeona Therapeutics
ABEO
$348M
$6.54M 0.04%
+80,000
New +$5.64M
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2019 Portfolio in Review

As of Q4 2019, Thomas Steyer held 132 positions worth $14.8B, up 12% from $13.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Thomas Steyer withdrew a net $1.22B in Q4 2019, closing 16 positions and reducing 29 holdings. Its most notable exit was Celgene Corp, an estimated $1.55B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 45% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Salesforce worth $281M.

  • Thomas Steyer's largest Q4 2019 buy was Salesforce: 1,724,880 shares worth $281M.
  • Thomas Steyer added most to Allergan plc in Q4 2019, an estimated $317M increase.
  • Thomas Steyer's biggest Q4 2019 reduction was Broadmark Realty Capital Inc. Common Stock, cutting an estimated $754M.
  • Thomas Steyer fully exited Celgene Corp in Q4 2019, selling an estimated $1.55B.
  • Thomas Steyer's ten largest holdings make up 44% of its $14.8B portfolio in Q4 2019.
  • Thomas Steyer opened 32 new positions and closed 16 in Q4 2019.
  • Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $14.8B.

Based on Farallon Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.